A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma

Zale P. Bernstein, Asher A Chanan Khan, Kena C. Miller, Donald W Northfelt, Gabriel Lopez-Berestein, Parkash S. Gill

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND. A multicenter trial was conducted to determine the efficacy and toxicity of escalating dosages of liposomal tretinoin (all-trans-retinoic acid) administered once or three times weekly in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma. METHODS. Seventy-six patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma were randomized to receive the study drug either once (n = 30) or 3 times weekly (n = 46). The starting dosage was 60 mg/m2, which was escalated to 90 mg/m2 and then 120 mg/m2 if the drug was well tolerated (≤ Grade 2 toxicities [according to the Southwest Oncology Group toxicity scale]). Four weeks of therapy constituted 1 cycle; patients could receive up to 8 cycles and those who completed 8 cycles were given the option of receiving extended therapy. Clinical response was defined as complete response (CR), partial response (PR), or stable disease (SD). RESULTS. Efficacy was assessed after the completion of 3 treatment cycles; 28.9% of patients (22 of 76 patients) responded (no CRs, 1 PR, and 21 SDs). Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs). Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183). CONCLUSIONS. Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma. A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.

Original languageEnglish (US)
Pages (from-to)2555-2561
Number of pages7
JournalCancer
Volume95
Issue number12
DOIs
StatePublished - Dec 15 2002

Fingerprint

Kaposi's Sarcoma
Tretinoin
Intravenous Administration
Acquired Immunodeficiency Syndrome
Therapeutics
Appointments and Schedules
Protease Inhibitors
Pharmaceutical Preparations
Multicenter Studies

Keywords

  • Acquired immunodeficiency virus (AIDS)
  • Human immunodeficiency virus (HIV)
  • Kaposi sarcoma (KS)
  • Liposomal tretinoin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. / Bernstein, Zale P.; Chanan Khan, Asher A; Miller, Kena C.; Northfelt, Donald W; Lopez-Berestein, Gabriel; Gill, Parkash S.

In: Cancer, Vol. 95, No. 12, 15.12.2002, p. 2555-2561.

Research output: Contribution to journalArticle

@article{a8dd82852c3946b4a30cee4cd229208c,
title = "A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma",
abstract = "BACKGROUND. A multicenter trial was conducted to determine the efficacy and toxicity of escalating dosages of liposomal tretinoin (all-trans-retinoic acid) administered once or three times weekly in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma. METHODS. Seventy-six patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma were randomized to receive the study drug either once (n = 30) or 3 times weekly (n = 46). The starting dosage was 60 mg/m2, which was escalated to 90 mg/m2 and then 120 mg/m2 if the drug was well tolerated (≤ Grade 2 toxicities [according to the Southwest Oncology Group toxicity scale]). Four weeks of therapy constituted 1 cycle; patients could receive up to 8 cycles and those who completed 8 cycles were given the option of receiving extended therapy. Clinical response was defined as complete response (CR), partial response (PR), or stable disease (SD). RESULTS. Efficacy was assessed after the completion of 3 treatment cycles; 28.9{\%} of patients (22 of 76 patients) responded (no CRs, 1 PR, and 21 SDs). Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7{\%}) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs). Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183). CONCLUSIONS. Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma. A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.",
keywords = "Acquired immunodeficiency virus (AIDS), Human immunodeficiency virus (HIV), Kaposi sarcoma (KS), Liposomal tretinoin",
author = "Bernstein, {Zale P.} and {Chanan Khan}, {Asher A} and Miller, {Kena C.} and Northfelt, {Donald W} and Gabriel Lopez-Berestein and Gill, {Parkash S.}",
year = "2002",
month = "12",
day = "15",
doi = "10.1002/cncr.11009",
language = "English (US)",
volume = "95",
pages = "2555--2561",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma

AU - Bernstein, Zale P.

AU - Chanan Khan, Asher A

AU - Miller, Kena C.

AU - Northfelt, Donald W

AU - Lopez-Berestein, Gabriel

AU - Gill, Parkash S.

PY - 2002/12/15

Y1 - 2002/12/15

N2 - BACKGROUND. A multicenter trial was conducted to determine the efficacy and toxicity of escalating dosages of liposomal tretinoin (all-trans-retinoic acid) administered once or three times weekly in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma. METHODS. Seventy-six patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma were randomized to receive the study drug either once (n = 30) or 3 times weekly (n = 46). The starting dosage was 60 mg/m2, which was escalated to 90 mg/m2 and then 120 mg/m2 if the drug was well tolerated (≤ Grade 2 toxicities [according to the Southwest Oncology Group toxicity scale]). Four weeks of therapy constituted 1 cycle; patients could receive up to 8 cycles and those who completed 8 cycles were given the option of receiving extended therapy. Clinical response was defined as complete response (CR), partial response (PR), or stable disease (SD). RESULTS. Efficacy was assessed after the completion of 3 treatment cycles; 28.9% of patients (22 of 76 patients) responded (no CRs, 1 PR, and 21 SDs). Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs). Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183). CONCLUSIONS. Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma. A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.

AB - BACKGROUND. A multicenter trial was conducted to determine the efficacy and toxicity of escalating dosages of liposomal tretinoin (all-trans-retinoic acid) administered once or three times weekly in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma. METHODS. Seventy-six patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma were randomized to receive the study drug either once (n = 30) or 3 times weekly (n = 46). The starting dosage was 60 mg/m2, which was escalated to 90 mg/m2 and then 120 mg/m2 if the drug was well tolerated (≤ Grade 2 toxicities [according to the Southwest Oncology Group toxicity scale]). Four weeks of therapy constituted 1 cycle; patients could receive up to 8 cycles and those who completed 8 cycles were given the option of receiving extended therapy. Clinical response was defined as complete response (CR), partial response (PR), or stable disease (SD). RESULTS. Efficacy was assessed after the completion of 3 treatment cycles; 28.9% of patients (22 of 76 patients) responded (no CRs, 1 PR, and 21 SDs). Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs). Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183). CONCLUSIONS. Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma. A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.

KW - Acquired immunodeficiency virus (AIDS)

KW - Human immunodeficiency virus (HIV)

KW - Kaposi sarcoma (KS)

KW - Liposomal tretinoin

UR - http://www.scopus.com/inward/record.url?scp=0037114717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037114717&partnerID=8YFLogxK

U2 - 10.1002/cncr.11009

DO - 10.1002/cncr.11009

M3 - Article

C2 - 12467070

AN - SCOPUS:0037114717

VL - 95

SP - 2555

EP - 2561

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -